登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C10H18O4
化学文摘社编号:
分子量:
202.25
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
GYKLFBYWXZYSOW-UHFFFAOYSA-N
SMILES string
CCCC(=O)OCOC(=O)C(C)(C)C
InChI
1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3
assay
≥95% (HPLC)
form
oil
color
colorless to slightly yellow
solubility
DMSO: ≥10 mg/mL
storage temp.
−20°C
Application
AN-9 is a HDAC inhibitor with antimetastatic and antiangiogenic properties. These anticancer activities are thought to occur by reducing vascularization and the expression of bFGF and HIF-1α.
Biochem/physiol Actions
HDAC Inhibitor tested as an anti-cancer drug; butyric acid pro-drug
存储类别
12 - Non Combustible Liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
T Kasukabe et al.
British journal of cancer, 75(6), 850-854 (1997-01-01)
A derivative of butyric acid, pivalyloxymethyl butyrate (AN-9), inhibited the proliferation and induced apoptosis of mouse monocytic leukaemia Mm-A cells, although sodium butyrate, but not AN-9, induced differentiation of the cells. AN-9 and DNA-specific antineoplastic agents synergistically inhibited the growth
Tony Reid et al.
Lung cancer (Amsterdam, Netherlands), 45(3), 381-386 (2004-08-11)
This multicenter phase II trial evaluated the therapeutic activity and safety profile of pivaloyloxymethyl butyrate (Pivanex, AN-9) as a single agent in refractory non-small cell lung cancer (NSCLC). Pivanex (2.34 g/m2 per day) was administered as a 6-h continuous intravenous
Suzanne M Cutts et al.
Molecular cancer therapeutics, 2(7), 661-670 (2003-07-29)
The anticancer anthracycline compound Adriamycin is a known topoisomerase II inhibitor but is also capable of exerting other cellular consequences. After intercalation, Adriamycin can form covalent adducts with DNA, and the magnitude of these adducts appears to be limited by
Belinda S Parker et al.
Oncology research, 14(6), 279-290 (2004-06-23)
The ability of mitoxantrone to form DNA adducts was investigated in a series of human tumor cell lines consisting of human cervical cancer (HeLa), human breast cancer (MCF-7), and human neuroblastoma (IMR-32) cells. The mitoxantrone-resistant human promyelocytic leukemia cell line
E Rabizadeh et al.
Leukemia research, 31(8), 1115-1123 (2007-02-03)
Chronic myelogenous leukemia (CML) is associated with the high TK activity chimeric protein BCR-ABL, known to contribute to cell tumorogenicity, resistance to apoptosis and differentiation. STI571, the TK inhibitor, is the current treatment for CML. One possible approach to overcome
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持